This study is being conducted by GW Pharma Ltd as a pilot study in order to determine the efficacy and safety of GWP42003 (0mg - 250mg twice daily), compared with placebo, by the percentage of participants achieving remission quantified as a Mayo score of 2 or less (with no subscore > 1) after 10 weeks treatment.